Quantum Biopharma Ltd. (QNTM) Form 6-K — Jun 2, 2026
Quantum Biopharma Ltd. announced that the U.S. FDA has placed its Investigational New Drug application for Lucid-MS on clinical hold, effective May 28, 2026. The agency requested additional information before permitting the planned Phase 2 trial to proceed, forcing the company to withdraw all previously disclosed timelines for trial initiation and interim data milestones.
Key figures
- Unbuzzd royalty cap usd
- 250000000
- Unbuzzd ownership percent
- 19.84
- Unbuzzd royalty rate initial
- 7
- Unbuzzd royalty rate post cap
- 3
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.